HDT Bio Receives $49M to Develop Vaccines for Deadly Viruses


Seattle-based biotech HDT Corp. announced a $49M funding round as part of a government project in partnership with the University of Texas Medical Branch (UTMB) and the U.S. Department of Defense and Department of Health and Human Services.

The UTMB-led project aims to create vaccines for two deadly viruses — Crimean-Congo hemorrhagic fever (CCHF) virus and Nipah virus (NiV), which has the potential to affect overseas military personnel. The funding intends to cover the successful completion of early vaccines trials. 

“We are grateful to DOD and HHS for their support,” said Steve Reed, HDT Bio’s co-founder and CEO. “We look forward to working with our partners … to protect our military personnel and the American people as a whole from biological threats.”